A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

By A. Hamberg, M. Dahl, M. Barban, M. Scordo, M. Wadelius, V. Pengo, R. Padrini, E. Jonsson. 2007

160 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing (2014, neutral): “As such, a long line of work [3] [14] [16] [21] [40] has sought pharmocogenetic models that can accurately predict proper dosage based on patient clinical history, demographics, and genotype.”
A Systems Approach to Designing Effective Clinical Trials Using Simulations (2012, methodology): “We extended a previously developed INR model based on PK/PD principles to model daily warfarin dosing for each clinical avatar.(14) In brief, a PK/PD model was estimated from a clinical trial of 150 Italian patients.”
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development (2012, methodology): “36 Work by Hamberg et al. 37 on warfarin exposure and response identified the CYP2C9 genotype and age as being predictive of exposure, and the VKORC1 genotype as being predictive of response.”